Moderna criticized for COVID-19 vaccine strategy putting once feel-good success story in jeopardy

Since it was approved 10 months ago, the Moderna COVID-19 vaccine has enjoyed a relatively unfettered run on its way to being considered one of the world’s two elite shots. But while COVID vaccine rival and pharmaceutical goliath Pfizer has faced a demanding spotlight, biotech Moderna has skipped along under the radar, avoiding scrutiny and gaining favor as a feel-good, success story. But that’s starting to change. With evidence mounting that other vaccine producers have made their shots more readily available to poorer countries, the shine is wearing off the Boston-based company. And with Tuesday’s revelation to the Associated Press that Moderna has no intention of sharing its mRNA vaccine formula with the rest of the world, the company has taken another public relations hit.